Trial Profile
Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2011
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms RECET
- 09 Aug 2011 New trial record